Literature DB >> 2293606

Effect of long-lasting diabetes mellitus on rat and human brain monoamines.

Z Lacković1, M Salković, Z Kuci, M Relja.   

Abstract

Experimental alloxan- or streptozotocin-produced diabetes in rats was accompanied by an increase in the levels of norepinephrine, dopamine, and serotonin, whereas the contents of metabolites, i.e., 5-hydroxyindoleacetic acid and homovanillic acid, in the whole brain gradually decreased with the duration of diabetes. Among the striatum, thalamus, and hypothalamus of alloxan diabetic rats, monoamine alterations were observed only in the hypothalamus; after 1 week an increase of norepinephrine content and after 13 weeks an increase of norepinephrine and dopamine contents were found. Tissues of 11 brain regions of 10 diabetic and 12 control patients post mortem were investigated for monoamine concentrations. Patients were all male, of similar age and interval between death and autopsy. Diabetic patients had an increase in the content of serotonin in the medial and lateral hypothalamus. The content of dopamine increased in the medial hypothalamus, putamen, and medial and lateral pallidus. In diabetic patients, the content of norepinephrine increased in the lateral pallidus and decreased in the nucleus accumbens and claustrum. Thus, it seems that diabetes mellitus in rats, as well as in humans is associated with regionally specific changes in brain monoamines.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2293606     DOI: 10.1111/j.1471-4159.1990.tb13294.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  21 in total

1.  Striatal dopaminergic D1 and D2 receptors after intracerebroventricular application of alloxan and streptozocin in rat.

Authors:  M Salković; I Sabolić; Z Lacković
Journal:  J Neural Transm Gen Sect       Date:  1995

2.  Hypothesis: Intensive insulin therapy-induced mortality is due to excessive serotonin autoinhibition and autonomic dysregulation.

Authors:  Undurti N Das
Journal:  World J Diabetes       Date:  2010-09-15

3.  Insulin modulates the strong reinforcing effects of nicotine and changes in insulin biomarkers in a rodent model of diabetes.

Authors:  Bryan Cruz; Rodolfo J Flores; Kevin P Uribe; Evangelina J Espinoza; Charles T Spencer; Katherine M Serafine; Arbi Nazarian; Laura E O'Dell
Journal:  Neuropsychopharmacology       Date:  2019-01-07       Impact factor: 7.853

4.  Enhanced beta-adrenergic receptors in the brain and pancreas during pancreatic regeneration in weanling rats.

Authors:  V Ani Das; Remya Robinson; C S Paulose
Journal:  Mol Cell Biochem       Date:  2006-04-01       Impact factor: 3.396

5.  MR spectroscopy of cerebral white matter in type 2 diabetes; no association with clinical variables and cognitive performance.

Authors:  Audrey Tiehuis; Femke van der Meer; Willem Mali; Marc Pleizier; Geert Jan Biessels; Jaap Kappelle; Peter Luijten
Journal:  Neuroradiology       Date:  2009-09-30       Impact factor: 2.804

6.  Hypoglycemia induced changes in cholinergic receptor expression in the cerebellum of diabetic rats.

Authors:  Sherin Antony; T Peeyush Kumar; Jobin Mathew; T R Anju; C S Paulose
Journal:  J Biomed Sci       Date:  2010-02-05       Impact factor: 8.410

7.  Curcumin modulates dopaminergic receptor, CREB and phospholipase C gene expression in the cerebral cortex and cerebellum of streptozotocin induced diabetic rats.

Authors:  T Peeyush Kumar; Sherin Antony; G Gireesh; Naijil George; C S Paulose
Journal:  J Biomed Sci       Date:  2010-05-31       Impact factor: 8.410

8.  Type 2 diabetes mellitus: A central nervous system etiology.

Authors:  Peter J Jannetta; Lynn H Fletcher; Peter M Grondziowski; Kenneth F Casey; Raymond F Sekula
Journal:  Surg Neurol Int       Date:  2010-07-16

9.  Altered thermoregulatory responses to clonidine in streptozotocin-diabetic rats.

Authors:  J M O'Donnell; T Banyasz; T Kovacs
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

Review 10.  Brain insulin dysregulation: implication for neurological and neuropsychiatric disorders.

Authors:  Rasoul Ghasemi; Leila Dargahi; Ali Haeri; Maryam Moosavi; Zahurin Mohamed; Abolhassan Ahmadiani
Journal:  Mol Neurobiol       Date:  2013-01-20       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.